

Special Issue on  
**Glaucoma Medical Therapy: Efficacy in the Respect of Safety**

# CALL FOR PAPERS

Glaucoma is a chronic and progressive condition of the optic nerve which can lead to visual field loss and blindness. The disease is often associated with elevated intraocular pressure (IOP). The aim of glaucoma treatment is to maintain the patients' visual function and related quality of life at a sustainable cost, where the "cost" refers not only to financial implications but also to therapies' side effects.

The first-choice treatment for glaucoma is the topical use of IOP-lowering medications, since IOP remains the most clinically important risk factor for developing and/or progressing glaucoma. Since glaucoma is a chronic disease, the long-term safety of a chronic and daily therapy is of paramount importance, affecting patients' quality of life (number of instillations, side effects, costs, etc.) and also influencing compliance and adherence and therefore the efficacy itself of the drug.

Here, we propose a special issue focusing on high-quality, original review articles and clinical studies that address the recent advances in the safety of glaucoma medications not only in terms of local and systemic side effects but also in terms of the impact on surgery outcome. We will solicit manuscripts also regarding drug safety and patients' compliance, adherence, and quality of life over time.

Potential topics include but are not limited to the following:

- ▶ Efficacy and safety of preserved versus unpreserved glaucoma medical therapies over time (papers reporting data with a follow-up of over 12 months will be very welcome)
- ▶ Safety and efficacy of newer fixed associations for glaucoma medical therapy
- ▶ Safety, adherence, and compliance: maximum tolerated glaucoma medical therapy
- ▶ Safety and quality of life: impact of glaucoma medications' side effects on quality of life perception
- ▶ Safety of glaucoma drugs in patients over 80 years of age
- ▶ IOP-lowering drugs' safety and glaucoma surgeries (papers reporting data about not only traditional surgery but also new MIGS and ocular surface status are particularly encouraged)

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/joph/smtg/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

**Lead Guest Editor**

Gemma Caterina Maria Rossi, IRCCS  
Policlinico San Matteo Foundation,  
Pavia, Italy  
*g.rossi@smatteo.pv.it*

**Guest Editors**

Teresa Rolle, Ospedale Oftalmico,  
Torino, Italy  
*teresa.rolle@unito.it*

Paolo Bettin, Ospedale San Raffaele,  
Milano, Italy  
*bettin63@gmail.com*

**Submission Deadline**

Friday, 22 June 2018

**Publication Date**

November 2018